Malicki S, Czarna A, Zyla E, Pucelik B, Galan W, Chruscicka B
Sci Rep. 2024; 14(1):28652.
PMID: 39562585
PMC: 11576874.
DOI: 10.1038/s41598-024-74891-7.
Malik M, Alqahtani M, Hadadi I, Kanbayti I, Alawaji Z, Aloufi B
Diagnostics (Basel). 2024; 14(21).
PMID: 39518426
PMC: 11545511.
DOI: 10.3390/diagnostics14212459.
Cao X, Mao X, Lu S, Zhu W, Huang W, Yi H
ACS Omega. 2024; 9(43):43826-43833.
PMID: 39494025
PMC: 11525735.
DOI: 10.1021/acsomega.4c06761.
Jung K, Kim M, Jung H, Koo H, Kim J, Lee H
Sci Rep. 2024; 14(1):17994.
PMID: 39097625
PMC: 11297922.
DOI: 10.1038/s41598-024-68987-3.
Weng D, Guo R, Zhu Z, Gao Y, An R, Zhou X
EJNMMI Res. 2023; 13(1):38.
PMID: 37129788
PMC: 10154443.
DOI: 10.1186/s13550-023-00982-7.
Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer.
Wang L, Luo S, Wang Z, Huang Y, Luo Y, Xie X
J Immunol Res. 2022; 2022:5160705.
PMID: 36405012
PMC: 9668476.
DOI: 10.1155/2022/5160705.
Nanotheranostic Strategies for Cancer Immunotherapy.
Nguyen A, Kumar S, Kulkarni A
Small Methods. 2022; 6(12):e2200718.
PMID: 36382571
PMC: 11056828.
DOI: 10.1002/smtd.202200718.
Prognostic Value of UBE2T and Its Correlation with Immune Infiltrates in Lung Adenocarcinoma.
Xu F, Xiong N, Yuan Y, Liu J
J Oncol. 2022; 2022:5244820.
PMID: 36245987
PMC: 9553516.
DOI: 10.1155/2022/5244820.
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.
Oriuchi N, Endoh H, Kaira K
Int J Mol Sci. 2022; 23(16).
PMID: 36012657
PMC: 9409366.
DOI: 10.3390/ijms23169394.
Glucose-Thymidine Ratio as a Metabolism Index Using F-FDG and F-FLT PET Uptake as a Potential Imaging Biomarker for Evaluating Immune Checkpoint Inhibitor Therapy.
Oh S, Youn H, Paeng J, Kim Y, Lee C, Choi H
Int J Mol Sci. 2022; 23(16).
PMID: 36012530
PMC: 9409370.
DOI: 10.3390/ijms23169273.
Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.
Li D, Li X, Zhao J, Tan F
J Transl Med. 2022; 20(1):358.
PMID: 35962347
PMC: 9373390.
DOI: 10.1186/s12967-022-03559-5.
In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET.
Ghai A, Fettig N, Fontana F, DiPersio J, Rettig M, O Neal J
EJNMMI Res. 2021; 11(1):97.
PMID: 34586539
PMC: 8481408.
DOI: 10.1186/s13550-021-00840-4.
Non-invasive molecular imaging of kidney diseases.
Klinkhammer B, Lammers T, Mottaghy F, Kiessling F, Floege J, Boor P
Nat Rev Nephrol. 2021; 17(10):688-703.
PMID: 34188207
PMC: 7612034.
DOI: 10.1038/s41581-021-00440-4.
A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Ga-labeled PD-L1 targeted nanobody.
Qin S, Yu Y, Guan H, Yang Y, Sun F, Sun Y
Aging (Albany NY). 2021; 13(9):13006-13022.
PMID: 33910164
PMC: 8148448.
DOI: 10.18632/aging.202981.
Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.
Khan A, Dias F, Neekhra S, Singh B, Srivastava R
Front Chem. 2021; 8:631351.
PMID: 33585406
PMC: 7878384.
DOI: 10.3389/fchem.2020.631351.
Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy.
Tremblay M, OBrien-Moran Z, Rioux J, Nuschke A, Davis C, Kast W
Oncoimmunology. 2020; 9(1):1851539.
PMID: 33299663
PMC: 7714509.
DOI: 10.1080/2162402X.2020.1851539.
Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer.
Nisar S, Bhat A, Hashem S, Yadav S, Rizwan A, Singh M
J Transl Med. 2020; 18(1):471.
PMID: 33298096
PMC: 7727217.
DOI: 10.1186/s12967-020-02656-7.
Development of [Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
Ghai A, Zheleznyak A, Mixdorf M, ONeal J, Ritchey J, Rettig M
Eur J Nucl Med Mol Imaging. 2020; 48(5):1302-1311.
PMID: 33179150
PMC: 8110592.
DOI: 10.1007/s00259-020-05097-y.
Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy.
Oriuchi N, Sugawara S, Shiga T
Biomedicines. 2020; 8(9).
PMID: 32972006
PMC: 7556039.
DOI: 10.3390/biomedicines8090371.
Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?.
Savic L, Doemel L, Schobert I, Montgomery R, Joshi N, Walsh J
Radiology. 2020; 296(3):575-583.
PMID: 32633675
PMC: 7434651.
DOI: 10.1148/radiol.2020200373.